What is ledipasvir/sofosbuvir?
Ledipasvir/sofosbuvir is a prescription medicine approved by the U.S. (FDA) for the treatment of chronic (HCV) in adults and in children 3 years of age and older who meet specific requirements, as determined by a health care provider. The medicine combines two drugs (ledipsavir and sofosbuvir) in a single tablet.
HCV is an What is an Opportunistic Infection? fact sheet.(OI) of HIV. An OI is an that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about OIs, read the HIVinfo
To learn how HIV and HCV are connected, read the HIVinfo HIV and Hepatitis C fact sheet. The fact sheet includes information about how HCV is spread, symptoms of HCV, and treatment options.
How is ledipasvir/sofosbuvir used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIVreference the AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating sofosbuvir to treat HCV infection in people with HIV.C, which includes recommendations on the use of ledipasvir/
The recommended uses may not always be consistent with FDA-approved uses of ledipasvir/sofosbuvir. See the guidelines for complete information on recommended uses of ledipasvir/sofosbuvir in adults and children with HIV. Some recommended uses, such as uses in certain rare circumstances, may have been omitted above.
What should I tell my health care provider before taking ledipasvir/sofosbuvir?
Before taking ledipasvir/sofosbuvir, tell your health care provider:
- If you are allergic to ledipasvir/sofosbuvir or any other medicines.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
- About any medical conditions you have or have had, for example, or kidney problems.
- If you are pregnant or plan to become pregnant. Whether ledipasvir/sofosbuvir can harm an unborn baby is unknown. Pregnancy should be avoided during combination treatment with ledipasvir/sofosbuvir and ribavirin and for 6 months after completion of the treatment. Talk to your health care provider about possible risks with taking ledipasvir/sofosbuvir during pregnancy.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Ledipasvir/sofosbuvir may affect the way other medicines or products work, and other medicines or products may affect how ledipasvir/sofosbuvir works. Ask your health care provider if there are interactions between ledipasvir/sofosbuvir and the other medicines you take.
How should I take ledipasvir/sofosbuvir?
Take ledipasvir/sofosbuvir according to your health care provider’s instructions. Your health care provider will tell you how much ledipasvir/sofosbuvir to take and when to take it. Before you start ledipasvir/sofosbuvir and each time you get a refill, read any printed information that comes with your medicine.
How should ledipasvir/sofosbuvir be stored?
- Store ledipasvir/sofosbuvir at room temperature, 68°F to 77°F (20°C to 25°C), below 86°F (30°C).
- Keep ledipasvir/sofosbuvir in the container that it came in and keep the container tightly closed. If the container has a small packet of drying agent (called a desiccant), do not remove it. The desiccant protects the medicine from moisture.
- Do not use ledipasvir/sofosbuvir if the original seal over the container opening is broken or missing.
- Throw away ledipasvir/sofosbuvir that is no longer needed or expired (out of date). Follow FDA guidelineson how to safely dispose of unused medicine.
- Keep ledipasvir/sofosbuvir and all medicines out of reach of children.
Where can I find more information about ledipasvir/sofosbuvir?
More information about ledipasvir/sofosbuvir is available:
- Recommendations on the HIV-related use of ledipasvir/sofosbuvir, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, prepared by the , the , and the HIV Medicine Association of the Diseases Society of America
- Recommendations on the HIV-related uses of ledipasvir/sofosbuvir, from the AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, prepared by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America
- Ledipasvir/sofosbuvir-related research studies, from
The above Patient Version drug summary is based on the following FDA label(s): Tablet (film coated).
Last Reviewed: September 6, 2019